Investor Presentaiton

Differentiated model-Regulated Markets Focus Global Footprint Acquired key players in major markets to expand its global footprint Regulatory Approvals These markets are empowered with regulatory approvals which allows the company to sell its products without restrictions Higher Margins Proven ability to generate higher margins by eliminating third parties from the value chain Proprietary Marketing Presence Among the few Indian players with a proprietary marketing presence in the world's largest pharma market such as US, UK and Australia 25+ Countries Market reach in 25+ countries with the UK and the US being the largest Expansion in Regulated Markets Proposed expansion in the regulated markets through integrated product development, cGMP compliance, regulatory compliance and utilization of latest technologies Expansion to other developed markets Other prominent markets include Australia, New Zealand, Canada and several other European countries ©2021 - Marksans Pharma Limited, All Rights Reserved. Revenue Contribution Generates ~95% of its revenues from regulated markets Revenue Mix 3.40% 3.00% 5.60% 4.20% 13.8% 10.9% 12.0% 12.4% 4.60% 10.6% 37.3% 45.5% 42.3% 41.3% 45.0% 45.5% 40.7% 41.1% 42.5% 38.5% FY17 FY18 FY19 FY20 FY21 US, North America Europe, UK ■Australia, NZ ROW 13

View entire presentation